Emergent BioSolutions Will Produce COVID-19 Antibody from Humanigen
Emergent BioSolutions has entered into an agreement to manufacture Humanigen’s lenzilumab, a potential treatment for COVID-19, ahead of an Emergency Use Authorization filing expected early this year.
Under the deal, Emergent will provide Humanigen access to manufacturing capability that was reserved by HHS since June 2020 via a public-private partnership. Production will occur in part at Emergent’s new Baltimore, Md., facility. Financial details of the agreement were not disclosed.
Lenzilumab is a monoclonal antibody currently being evaluated in a phase 3 study for hospitalized COVID-19 patients who suffer from the overactive immune response known as cytokine storm. The study is expected to be completed in March, according to ClinicalTrials.gov.
The drug is also being evaluated in the National Institutes of Health’s ACTIV-5 phase 2 trial assessing COVID-19 treatments, which is expected to conclude at the end of 2021.